Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian
The standard of care for DLBCL and double-hit lymphoma
Why it is important to individualize care for multiple myeloma patients
Is venetoclax appropriate for relapsed CLL patients?
Next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma